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The California Institute for Regenera-
tive Medicine (CIRM) recently granted 
?$230 million in Disease Team 
Research Awards to get stem cell-
based therapies into the clinic within 4 
years (http://www.cirm.ca.gov). Up to 
?$20 million will go to each of 14 Cal-
ifornia-based interdisciplinary research 
groups, with the first funding checks to 
be sent out next month. The expecta-
tion is that within 4 years each group 
will submit an Investigational New Drug 
(IND) application to the US Food and 
Drug Administration (FDA) for a phase I 
clinical trial. To receive the funding, the 
research teams are required to include 
basic scientists and clinicians from aca-
demia and industry, with the goal of get-
ting test agents rapidly into clinical trials 
and addressing clinical issues early in 
the research process. CIRM’s Presi-
dent, Alan Trounson, estimates that 
75% of the projects funded will result in 
IND applications to the FDA within the 
4 year funding period. “I am impressed 
with these teams—some have already 
had pre-application meetings with the 
FDA,” says Trounson. He emphasizes 
that all of the Disease Teams include 
researchers that have been through the 
IND application process.
The CIRM-funded projects pro-
pose to develop new stem cell ther-
apies to treat 11 diseases including 
AIDS, diabetes, sickle-cell anemia, 
amyotrophic lateral sclerosis (ALS), 
ischemic heart disease, several 
different types of cancer, stroke, 
macular degeneration, and the rare 
genetic skin disease dystrophic epi-
dermolysis bullosa. “We were open 
to all stem cell approaches and 
wanted to include as many diseases 
as possible, especially those with no 
cures…we wanted to see creative 
uses of stem cells and encouraged 
investigators to aim higher and bite 
off bigger chunks than in most grant 
applications,” says Bettina Steffen, Sci-
ence Officer at CIRM. The review com-
mittees “considered any role of the stem 
cell as part of the actual therapeutic or 
even as part of a screening platform to 
identify drugs,” she adds.
Some of the more advanced projects 
are variations on current clinical prac-
tices. Two separate groups—one led by 
Irving Chen at UCLA (awarded almost $20 
million) and one by John Zaia (awarded 
$14.5 million) from the City of Hope Medi-
cal Center in Duarte, CA—received fund-
ing to develop autologous hematopoietic 
stem cell transplantation therapies for 
patients with AIDS. These projects aim to 
reduce expression of the HIV coreceptor 
CCR5 on hematopoietic stem cells from 
AIDS patients, each by a different mecha-
nism. After transplantation of the modi-
fied hematopoietic stem cells back into 
the patient, the stem cells differentiate 
into lymphocytes that should be resistant 
to infection by HIV. Many AIDS patients 
already receive bone marrow transplants 
for AIDS-related lymphoma, and loss of 
HIV replication has been reported in an 
AIDS patient with leukemia who received 
bone marrow stem cells expressing a 
nonfunctional form of CCR5.
Steffen explains that “some of the 
studies funded are on a more-articulated 
path to an IND, facilitated by past expe-
rience.” The CIRM money will be used 
by the AIDS research teams to optimize 
the modification of hematopoietic stem 
cells. Zaia’s team disrupts the CCR5 
gene sequence using zinc-finger nucle-
ases, and Chen’s team plans to down-
regulate CCR5 expression in hematopoi-
etic stem cells using lentiviral vectors 
expressing small hairpin RNAs. “It’s dif-
ficult to get funding for these types of 
preclinical studies,” says Chen. “We will 
use the money to get the vector into the 
stem cells, select the best patient popu-
lation, and investigate different means of 
myeloablative therapies.”
One project receiving CIRM fund-
ing that Trounson predicts will result 
in an IND submission within 2 years is 
spearheaded by Eduardo Marbán of 
the Cedars-Sinai Heart Institute in Los 
Angeles (Figure 1). Marbán has been 
given $5.5 million to isolate and expand 
cardiac stem cells from patients with 
advanced ischemic cardiomyopathy. The 
goal is to inject the stem cells back into 
the cardiac muscle to repair the dam-
aged tissue and form new cardiac mus-
cle and blood vessels. Cardiac stem 
cells are already being tested in a 
phase I/II clinical trial of 13 patients, 
funded by the National Institutes of 
Health (NIH) (http://clinicaltrials.gov/
ct2/show/NCT00893360). Another 
?1000 patients are being treated 
with bone marrow-derived cells to 
test their effects in improving car-
diac function. “These cells have a 
good safety protocol but marginal 
efficacy,” says Marbán.
The CIRM funding will allow 
Marbán’s team to compare the 
effects of two different types of 
autologous cardiac stem cells 
(cardiospheres and individual car-
diosphere-derived cells), investi-
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Figure 1. CIRM Grants for Stem Cell Therapies
Eduardo Marbán, director of the Cedars-Sinai Heart Institute 
in Los Angeles, has been awarded $5.56 million by CIRM to 
develop cardiac stem cells for treating heart disease. Photo 
courtesy of Cedars-Sinai Heart Institute.
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gate the effects of injecting the cells 
directly into cardiac muscle, and test 
stem cell efficacy in patients at more 
advanced stages of heart failure. 
“There is an absence of NIH funds to 
get from clever mechanistic insights 
to new treatments…CIRM’s funding 
makes deliverables achievable,” says 
Marbán.
Although the NIH provides funding 
for the basic research that leads to 
new therapeutic strategies, it provides 
little for the pharmacokinetic, toxicol-
ogy, and scale-up experiments that are 
needed to prepare an IND application 
for the FDA. As a result, many scientists 
have to hand off their ideas to biotech-
nology or pharmaceutical companies 
at this stage of development. “Before 
the CIRM money, our options were to 
license our antibody or start our own 
biotech company,” says Ravi Majeti, 
co-principal investigator with Irving 
Weissman at Stanford University; their 
team received ?$20 million to gener-
ate a monoclonal antibody to destroy 
leukemia stem cells. “We can use the 
CIRM funds to develop this therapeutic 
inside the academic arena—to pursue 
an optimal cure strategy [for leukemia], 
not just establish antibody efficacy and 
try to get the antibody onto the market 
like a drug company would do.” Many 
recipients of CIRM funds say that the 
money would allow them to keep their 
therapeutic approach in their own lab 
and optimize an overall treatment strat-
egy. “At a company, the goal is the bot-
tom line—we want to continue to inves-
tigate the biology of this approach,” 
says Majeti.
“The CIRM funding is a dream 
made in heaven,” says Stanford sci-
entist Garry Nolan, of the ?$20 million 
grant his multidisciplinary team was 
awarded to develop small-molecule 
drugs against cancer-initiating cells in 
solid tumors. The team, which includes 
oncologist Dennis Slamon (UCLA) and 
signaling researcher Tak Mak (Univer-
sity of Toronto), is one of only a few 
that can identify cancer stem cells in 
tumors of the brain, colon, and ovary. 
These investigators have developed 
assays to accurately test the effective-
ness of drug candidates in killing can-
cer stem cells. Although they haven’t 
stated what specific type of drug they 
plan to develop, Nolan says they plan 
to target novel kinases that they expect 
to identify in cancer-initiating cells. “I 
can’t imagine pulling together an NIH 
grant to do this; it wouldn’t fund some-
thing so bench-to-bedside or so high-
risk,” says Nolan.
Some of the Disease Team Research 
Awards have gone to projects that are 
still at very early stages of development 
and have large obstacles to overcome 
before they can be turned into clinical 
trial proposals. The Stanford team of 
Alfred Lane, Anthony Oro, and Marius 
Wernig has been awarded a CIRM grant 
of ?$12 million to derive induced pluri-
potent stem (iPS) cells from the skin 
of patients with the blistering skin dis-
ease epidermolysis bullosa. The goal 
is to replace the abnormal collagen VII 
(COL7A1) gene that causes this disease 
with the wild-type gene in the skin-
derived iPS cells. Then the corrected 
iPS cells will be induced to differenti-
ate into basal keratinocytes that will be 
used to make sheets of epidermis for 
grafting. This project, however, is still 
in its infancy. Before the researchers 
can even begin to think about an IND 
application, they must demonstrate 
homologous recombination at the 
COL7A1 locus in iPS cells, coax the iPS 
cells to differentiate into keratinocytes, 
and then evaluate the efficacy and tox-
icity of the corrected keratinocytes in 
a human tissue model of epidermoly-
sis bullosa—a decade-long project for 
most laboratories.
“We’re optimistic, but we need a lot 
of things to go right,” says Oro. “It’s 
remarkable how fast the stem cell field 
is moving.” Although this project is a 
long-shot to get to the FDA in 4 years, 
it is important because there are no 
therapeutic options for patients with 
epidermolysis bullosa. The reviewers 
of Oro’s grant proposal also pointed 
out that discoveries made through this 
effort will advance the use of iPS cell-
derived therapies for other  disorders.
“There are a lot of challenges to some 
of the projects,” says Trounson. “Some 
of the teams know that they have to 
clear some major hurdles within the 
first year; these groups have to get off 
to a quick start.” The progress of each 
team will be evaluated informally each 
quarter and in a formal presentation 
each year to an established committee 
of independent, non-CIRM scientists. 
“After one year, go/no-go decisions will 
be made for each project—if the teams 
don’t meet their milestones, we won’t 
allocate any more funds to the project,” 
warns Trounson.
CIRM has developed a tough repu-
tation of intensive oversight for all of 
the projects that it funds—3 of the 73 
“Scientific Excellence through Explo-
ration and Development” projects they 
funded in 2007 were recently revoked 
because of inadequate progress. “Most 
academic scientists are not used to this 
kind of oversight,” says Oro. “It’s dif-
ferent from submitting an NIH progress 
report every few years—it’s more like 
industry.” Marbán emphasizes that he 
thinks it is healthy for grants to be held 
accountable in terms of deliverables. 
However, he says, “I hope the agency 
will be open to opportunities created 
by new discoveries—we wouldn’t want 
to be tied to the original plan if it was 
based on outdated data. I am optimis-
tic it will be an iterative process.”
Nonetheless, some stem cell 
researchers believe that many more 
basic science questions should be 
answered before these cells can be put 
into patients. George Daley, Director of 
the Stem Cell Transplantation Program 
at Children’s Hospital Boston, says, 
“outside the blood, the field of stem 
cell treatments is in its infancy. We 
are still ignorant about how products 
of pluripotent stem cells will behave in 
vivo. We’re still learning about differ-
entiation, function, and engraftment… 
I don’t know of many cell products 
based on embryonic stem cells that are 
ready for clinical application.”
Lawrence Goldstein (University of 
California, San Diego), co-principal 
investigator of a team that received 
a $15.6 million CIRM grant to gener-
ate astrocyte precursors from human 
embryonic stem cells (hESCs) to treat 
ALS, believes that clinical research 
should push forward. “We think we 
know what happens to these cells in 
vivo. They seem to integrate. Do they 
move to other tissues? We don’t know 
yet. We hope that they’re going to func-
tion as astrocytes in the spinal cord but 
it’s going to take us a while to find out.” 
Only four of the Disease Team Research 
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Awards were granted to groups devel-
oping hESC therapies. Research on 
hESCs is still in its early stages and 
faces many controversies and chal-
lenges. A phase I clinical trial by Geron, 
a California-based biotech company, to 
test oligodendrocyte progenitor cells 
derived from hESCs to treat patients with 
spinal cord injury was recently halted 
because of findings from animal studies 
that raised safety concerns. Goldstein 
admits, “This is pretty early days—we 
have genetic evidence that the astro-
cytes are good targets [for treating ALS] 
… but the details of all the things they’re 
doing is not clear; it may not be clear 
for a while. The goal is not necessarily 
to know what’s going on, the goal is to 
find a way to make these cells safe and 
effective and transplantable.”
The pressure is on CIRM to provide 
new stem cell-based therapeutics for the 
people of California, who in 2004 voted 
to support Proposition 71, a ballot ini-
tiative to provide $3 billion for stem cell 
research. “Californians don’t care if we 
get 100 Cell papers out of this research,” 
says Trounson; “for the community to 
recognize our accomplishments, we 
need to demonstrate clinical benefits.” 
According to Trounson, CIRM is cur-
rently spending about $200 million/year 
on stem cell research, with the expec-
tation that CIRM’s funding will last at 
least through 2016. At that point, CIRM 
hopes to have sufficient therapies 
developed to encourage industry and 
venture capital firms to continue fund-
ing CIRM’s stem cell research.
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